IHT Wealth Management LLC Has $642,000 Position in AstraZeneca PLC (NASDAQ:AZN)

IHT Wealth Management LLC lifted its position in shares of AstraZeneca PLC (NASDAQ:AZN – Get Rating) by 21.0% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 11,703 shares of the company’s stock after purchasing an additional 2,031 shares during the quarter. IHT Wealth Management LLC’s holdings in AstraZeneca were worth $642,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Parkside Financial Bank & Trust boosted its position in AstraZeneca by 4,875.0% during the first quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock valued at $26,000 after purchasing an additional 390 shares during the last quarter. Hazlett Burt & Watson Inc. boosted its position in AstraZeneca by 129.5% during the third quarter. Hazlett Burt & Watson Inc. now owns 514 shares of the company’s stock valued at $28,000 after purchasing an additional 290 shares during the last quarter. Fairfield Bush & CO. acquired a new stake in shares of AstraZeneca in the first quarter valued at approximately $28,000. Great West Life Assurance Co. Can lifted its position in shares of AstraZeneca by 102.7% in the first quarter. Great West Life Assurance Co. Can now owns 525 shares of the company’s stock valued at $36,000 after buying an additional 266 shares during the last quarter. Finally, Carolinas Wealth Consulting LLC acquired a new stake in shares of AstraZeneca in the third quarter valued at approximately $38,000. 16.42% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Price Performance

AstraZeneca stock opened at $65.61 on Friday. The stock’s fifty day moving average price is $67.03 and its two-hundred day moving average price is $63.39. AstraZeneca PLC has a one year low of $52.65 and a one year high of $72.12. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.86 and a quick ratio of 0.68. The firm has a market cap of $203.37 billion, a PE ratio of 61.32, a price-to-earnings-growth ratio of 1.19 and a beta of 0.51.

AstraZeneca Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Monday, March 27th. Shareholders of record on Friday, February 24th will be paid a dividend of $0.985 per share. This represents a yield of 2%. The ex-dividend date is Thursday, February 23rd. This is a positive change from AstraZeneca’s previous semi-annual dividend of $0.47. AstraZeneca’s dividend payout ratio (DPR) is 180.38%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on AZN shares. TheStreet raised AstraZeneca from a “c” rating to an “a” rating in a research report on Monday, December 5th. UBS Group increased their target price on AstraZeneca from £101 ($123.10) to £119 ($145.03) in a research note on Tuesday, February 21st. JPMorgan Chase & Co. increased their target price on AstraZeneca from £125 ($152.35) to £135 ($164.53) in a research note on Tuesday, January 3rd. BMO Capital Markets assumed coverage on AstraZeneca in a research note on Thursday, January 5th. They set an “outperform” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft increased their target price on AstraZeneca from £120 ($146.25) to £130 ($158.44) in a research note on Thursday, December 15th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, AstraZeneca presently has an average rating of “Hold” and an average price target of $10,825.11.

AstraZeneca Profile

(Get Rating)

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.